SCHEMBL22356151

SCHEMBL22356151

COC(=O)[C@H](C)OC(N)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 3/20 0.40
TSHR P16473 3/20 0.40
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
CYP2C9 P11712 1/20 0.40
MAPT P10636 1/20 0.39
CA12 O43570 2/20 0.35
ALOX15 P16050 1/20 0.35
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA4 P43681 1/20 0.33
CYP3A4 P08684 1/20 0.33
NFKB1 P19838 1/20 0.33
ADRA1A P35348 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14783842 1.00 CA14 (0.43) CA14SMN1; SMN2LMNATSHRCHRM2
SCHEMBL22356006 1.00 CA14 (0.43) CA14SMN1; SMN2LMNATSHRCHRM2
SCHEMBL23544806 0.80 LMNA (0.40) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL27789979 0.80 LMNA (0.40) LMNATSHRCHRM2CHRM4CHRM5
SCHEMBL28101759 0.80 TSHR (0.42) CA14LMNATSHRCHRM2CHRM4
SCHEMBL10012464 0.79 SMN1; SMN2 (0.44) CA14SMN1; SMN2TSHRMAPTCA12
SCHEMBL13741138 0.77 SMN1; SMN2 (0.42) CA14SMN1; SMN2TSHRCA12ALDH1A1
SCHEMBL10017663 0.77 SMN1; SMN2 (0.42) CA14SMN1; SMN2TSHRCA12ALDH1A1
SCHEMBL13741176 0.77 SMN1; SMN2 (0.42) CA14SMN1; SMN2TSHRCA12ALDH1A1
SCHEMBL4446595 0.77 SMN1; SMN2 (0.42) CA14SMN1; SMN2TSHRCA12ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11040048-B2 Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug SHIONOGI & CO., LTD. (JP) 2021-06-22 US disclosed
US-20200261481-A1 A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG SHIONOGI & CO., LTD. (JP) 2020-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200261481-A1 A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG RNASEH1, RNASEL, RNPEP CA14 43/4885SMN1; SMN2 4589/4885LMNA 1560/4885
US-11040048-B2 Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug RNASEH1, RNPEP, RNASEL CA14 33/4885SMN1; SMN2 4672/4885LMNA 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.